What is the share price of Entero Healthcare Solutions Ltd (ENTERO) today?
The share price of ENTERO as on 15th September 2026 is ₹1800. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Entero Healthcare Solutions Ltd (ENTERO) share?
The past returns of Entero Healthcare Solutions Ltd (ENTERO) share are- Past 1 week: -2.10%
- Past 1 month: 34.30%
- Past 3 months: 62.63%
- Past 6 months: 77.29%
- Past 1 year: 53.43%
- Past 3 years: N/A%
- Past 5 years: 57.92%
What are the peers or stocks similar to Entero Healthcare Solutions Ltd (ENTERO)?
The peers or stocks similar to Entero Healthcare Solutions Ltd (ENTERO) include:What is the market cap of Entero Healthcare Solutions Ltd (ENTERO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Entero Healthcare Solutions Ltd (ENTERO) is ₹7901.18 Cr as of 15th September 2026.What is the 52 week high and low of Entero Healthcare Solutions Ltd (ENTERO) share?
The 52-week high of Entero Healthcare Solutions Ltd (ENTERO) is ₹1920 and the 52-week low is ₹944.What is the PE and PB ratio of Entero Healthcare Solutions Ltd (ENTERO) stock?
The P/E (price-to-earnings) ratio of Entero Healthcare Solutions Ltd (ENTERO) is 68.69. The P/B (price-to-book) ratio is 4.51.Which sector does Entero Healthcare Solutions Ltd (ENTERO) belong to?
Entero Healthcare Solutions Ltd (ENTERO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Entero Healthcare Solutions Ltd (ENTERO) shares?
You can directly buy Entero Healthcare Solutions Ltd (ENTERO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Entero Healthcare Solutions Ltd
ENTERO Share Price
NSE₹1,800.000.85% (-15.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ENTERO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
ENTERO Performance & Key Metrics
ENTERO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 63.00 | 4.51 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.80 | 5.89 | 0.49% |
100%
Analysts have suggested that investors can buy this stock
from 5 analysts
Price Upside
Earnings Growth
Rev. Growth
ENTERO Company Profile
Entero Healthcare Solutions is an India-based technology-driven and integrated healthcare products distribution company.
SUNPHARMA
PE Ratio
38.46
38.46
1Y Return
14.31%
14.31%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
87.30
87.30
1Y Return
38.56%
38.56%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.15
22.15
1Y Return
7.23%
7.23%
Buy Reco %
57.69
57.69
CIPLA
PE Ratio
28.45
28.45
1Y Return
12.48%
12.48%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
119.70
119.70
1Y Return
119.85%
119.85%
Buy Reco %
58.33
58.33
ENTERO Sentiment Analysis
ENTERO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ENTERO Stock Summary · August 2026
Management said the quarter marked an acceleration in growth and an early delivery of its full-year profitability goal, with consolidated revenue up 38.2% year on year to INR 1,940 crores and EBITDA margin at 5%. It said like-for-like growth was even stronger at 40%, driven by organic momentum that outpaced the underlying pharmaceutical market and by calendarization of acquisitions completed last year, with no new deals closed in the quarter. Management emphasized that gross margin, EBITDA and PAT all rose sharply, while capital efficiency improved, as ROCE nearly doubled to 21.1% and ROE rose to 20.4%. It pointed to procurement efficiencies, a richer MedTech mix and the exit from low-margin accounts as key margin drivers, and described MedTech as its main medium-term margin lever. The company also highlighted stronger working-capital discipline, with net working capital days improving to 61. Looking ahead, management reaffirmed about 23% revenue growth and a 5% EBITDA margin for FY27, said margins could sustain or improve from here, and indicated it would remain selective on acquisitions while focusing on integrating the existing platform.
ENTERO Stock Growth Drivers
ENTERO Stock Growth Drivers
8Strong Revenue Growth Outpacing the Market
The company delivered a strong start to FY27 with consolidated revenue up 38.2% year on
Margin Expansion and Profitability Leverage
Profitability improved sharply, with EBITDA margin rising to 5% and gross margin expanding by 147
ENTERO Stock Challenges
ENTERO Stock Challenges
1Rising Interest Burden from Acquisition Debt
Interest expense is increasing as a result of acquisition-related borrowing, and the burden is expected
ENTERO Forecast
ENTERO Forecasts
Price
Revenue
Earnings
ENTERO Share Price Forecast
ENTERO Share Price Forecast
2026
Current
₹1,815.40
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,815.40
Baseline
Forecast for Sep 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ENTERO Company Revenue Forecast
ENTERO Company Revenue Forecast
2026
Current
₹6.61
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹6.61
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ENTERO Stock EPS (Earnings Per Share) Forecast
ENTERO Stock EPS (Earnings Per Share) Forecast
2026
Current
₹26.44
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹26.44
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ENTERO
ENTERO
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ENTERO Income Statement
ENTERO Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,043.33 | 1,110.47 | 1,311.97 | 1,366.49 | 1,346.35 | 1,409.64 | 1,575.74 | 1,711.13 | 1,913.94 | 1,943.50 | ||||||||||
Operating & Other expenses | 1,005.30 | 1,066.86 | 1,258.24 | 1,308.98 | 1,290.14 | 1,353.75 | 1,508.88 | 1,646.92 | 1,823.89 | 1,843.51 | ||||||||||
EBITDA | 38.03 | 43.61 | 53.73 | 57.51 | 56.21 | 55.89 | 66.86 | 64.21 | 90.05 | 99.99 | ||||||||||
| Depreciation/Amortization | 7.14 | 6.61 | 7.49 | 8.10 | 8.49 | 8.87 | 9.83 | 9.80 | 14.79 | 12.31 | ||||||||||
| PBIT | 30.89 | 37.00 | 46.24 | 49.41 | 47.72 | 47.02 | 57.03 | 54.41 | 75.26 | 87.68 | ||||||||||
| Interest & Other Items | 17.32 | 9.70 | 11.46 | 9.97 | 10.49 | 10.66 | 12.40 | 14.01 | 17.31 | 20.57 | ||||||||||
| PBT | 13.57 | 27.30 | 34.78 | 39.44 | 37.23 | 36.36 | 44.63 | 40.40 | 57.95 | 67.11 | ||||||||||
| Taxes & Other Items | -7.40 | 7.22 | 11.16 | 14.00 | 11.55 | 8.56 | 13.02 | 12.77 | 29.94 | 28.95 | ||||||||||
| Net Income | 20.97 | 20.08 | 23.62 | 25.44 | 25.68 | 27.80 | 31.61 | 27.63 | 28.01 | 38.16 | ||||||||||
| EPS | 5.73 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
ENTERO Company Updates
FY 2027FY 2027
Investor Presentation
Aug 7PDF
ENTERO Stock Peers
ENTERO Past Performance & Peer Comparison
ENTERO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Entero Healthcare Solutions Ltd | 68.69 | 4.51 | — |
| Sun Pharmaceutical Industries Ltd | 38.46 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 87.30 | 10.74 | 0.68% |
| Zydus Lifesciences Ltd | 22.15 | 3.77 | 0.09% |
ENTERO Stock Price Comparison
Compare ENTERO with any stock or ETFCompare ENTERO with any stock or ETF
ENTERO
ENTERO Holdings
ENTERO Shareholdings
ENTERO Promoter Holdings Trend
ENTERO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ENTERO Institutional Holdings Trend
ENTERO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ENTERO Shareholding Pattern
ENTERO Shareholding Pattern
ENTERO Shareholding History
ENTERO Shareholding History
Foreign Institutions
Mutual Funds Invested in ENTERO
Mutual Funds Invested in ENTERO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Entero Healthcare Solutions Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.9790% | Percentage of the fund’s portfolio invested in the stock 1.14% | Change in the portfolio weight of the stock over the last 3 months 0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 53/79 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0915% | Percentage of the fund’s portfolio invested in the stock 1.23% | Change in the portfolio weight of the stock over the last 3 months -0.46% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/41 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9084% | Percentage of the fund’s portfolio invested in the stock 2.43% | Change in the portfolio weight of the stock over the last 3 months 0.63% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 49/91 (+4) |
Compare 3-month MF holding change on Screener
smallcases containing ENTERO stock
smallcases containing ENTERO stock
Looks like this stock is not in any smallcase yet.
ENTERO Events
ENTERO Events
ENTERO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ENTERO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ENTERO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ENTERO has not given any dividends in last 5 years
ENTERO Dividends
ENTERO Dividends
Hmm, looks like data is unavailable here. Please come back after some timeENTERO Stock News & Opinions
ENTERO Stock News & Opinions
Articles & Videos
Corporate
Corporate
Rajesh Dalal resigned from Entero Healthcare roles following the conclusion of his director tenureEntero Healthcare Solutions Limited informed the BSE and NSE that the tenure of Rajesh Shashikant Dalal (DIN: 03504969) as Non-Executive Independent Director concluded on August 24, 2026, resulting in his resignation as Chairperson of the Nomination and Remuneration Committee, Stakeholders Relationship Committee, and member of the Audit Committee.
3 weeks agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions Ltd consolidated sales up 1.60% on year in Q2FY2026, net profit rose by 15.33%Entero Healthcare Solutions Ltd share price slipped 1.30% to Rs 1241.55. The Company's net profit improved by 15.33% to Rs 52.05 crore, while revenue from operations improved marginally 1.60% to Rs 1940.5 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmacy Retail industry group stocks on BSE stood at Rs 15833.4 crore, rising 1.21%. It has slipped by 1.34% over last one week and dropped by 13.48% in last one month while the market capitalization of Entero Healthcare Solutions Ltd has softened by 0.25% and 1.40% in the same period respectively. Profit before tax (PBT) of Entero Healthcare Solutions Ltd stood at Rs 67.12 crore in Q2 FY26, surging by 84.60% year-on-year, and jumping 15.82% quarter-on-quarter. EBITDA came in at Rs 94 crore, expanding by 112.45% YoY and improving 14.58% sequentially. Total expenses inched up 0.93% to Rs 1855.81 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 69.42 crore, rising by 7.20% YoY. For the TTM ended FY26, revenue from operations soared by 29.35% to Rs 6591.21 crore, while net profit jumped 35.75% to Rs 145.84 crore, compared to previous TTM. EBITDA surged by 14364% to Rs 246.71 crore, and PBT witnessed a strong rise of 29.26% to Rs 179.34 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 96.2 crore in FY26, as against Rs 76.86 crore in FY25. Entero Healthcare Solutions Ltd declined by 2.21% in last one year, performing in line with the benchmark BSE Sensex which has slipped by 1.97% during the same period.
1 month agoCapital Market - Live
Corporate
Corporate
Entero Healthcare's subsidiary, Qurovia Lifesciences, incorporated in India with Rs 1,00,000 investmentEntero Healthcare Solutions Limited informed the Bombay Stock Exchange and National Stock Exchange that its step-down subsidiary, Qurovia Lifesciences Private Limited, was incorporated in India on July 25, 2026, with its registered office in Bangalore, Karnataka. Qurovia, which will focus on the wholesale and retail distribution of pharmaceuticals and healthcare products, was incorporated with an authorized share capital of Rs 1,50,00,000 and R S M Pharma Private Limited, a wholly owned subsidiary of Entero Healthcare Solutions Limited, subscribed to 10,000 equity shares, aggregating to Rs 1,00,000.
1 month agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to announce Quarterly ResultEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 7 August 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to convene AGMEntero Healthcare Solutions announced that the 8th Annual General Meeting(AGM) of the company will be held on 19 August 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 9.03% in the March 2026 quarterNet profit of Entero Healthcare Solutions rose 9.03% to Rs 28.01 crore in the quarter ended March 2026 as against Rs 25.69 crore during the previous quarter ended March 2025. Sales rose 42.63% to Rs 1909.93 crore in the quarter ended March 2026 as against Rs 1339.06 crore during the previous quarter ended March 2025. For the full year,net profit rose 21.32% to Rs 115.04 crore in the year ended March 2026 as against Rs 94.82 crore during the previous year ended March 2025. Sales rose 29.35% to Rs 6591.21 crore in the year ended March 2026 as against Rs 5095.78 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1909.931339.06 43 6591.215095.78 29 OPM %4.503.65 -4.033.37 - PBDT72.7445.72 59 230.81169.43 36 PBT57.9537.23 56 187.52138.74 35 NP28.0125.69 9 115.0494.82 21 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to discuss resultsEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 25 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 8.61% in the December 2025 quarterNet profit of Entero Healthcare Solutions rose 8.61% to Rs 27.63 crore in the quarter ended December 2025 as against Rs 25.44 crore during the previous quarter ended December 2024. Sales rose 25.57% to Rs 1706.52 crore in the quarter ended December 2025 as against Rs 1359.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1706.521359.00 26 OPM %3.973.68 - PBDT58.3847.54 23 PBT48.5839.44 23 NP27.6325.44 9 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Entero Healthcare Solutions to hold board meetingEntero Healthcare Solutions will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Entero Healthcare Solutions consolidated net profit rises 33.78% in the September 2025 quarterNet profit of Entero Healthcare Solutions rose 33.78% to Rs 31.60 crore in the quarter ended September 2025 as against Rs 23.62 crore during the previous quarter ended September 2024. Sales rose 20.78% to Rs 1570.95 crore in the quarter ended September 2025 as against Rs 1300.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1570.951300.69 21 OPM %3.953.26 - PBDT54.4642.27 29 PBT44.6334.78 28 NP31.6023.62 34 Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 29.95%, vs industry avg of 11.78%
Over the last 5 years, market share increased from 0.61% to 1.29%